Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.020
+0.100 (5.21%)
Aug 12, 2025, 3:18 PM - Market open
Chuy's Holdings Revenue
Fortress Biotech had revenue of $13.14M in the quarter ending March 31, 2025, with 0.84% growth. This brings the company's revenue in the last twelve months to $57.78M, down -32.11% year-over-year. In the year 2024, Fortress Biotech had annual revenue of $57.68M, down -31.76%.
Revenue (ttm)
$57.78M
Revenue Growth
-32.11%
P/S Ratio
0.77
Revenue / Employee
$572,119
Employees
101
Market Cap
59.73M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.68M | -26.84M | -31.76% |
Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
FBIO News
- 5 days ago - Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 - GlobeNewsWire
- 6 days ago - Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 4 weeks ago - Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™ - GlobeNewsWire
- 7 weeks ago - Journey Medical to Join Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference - GlobeNewsWire
- 2 months ago - Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV - GlobeNewsWire
- 2 months ago - Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - GlobeNewsWire
- 3 months ago - Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire